Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations. Activity participants will also explore strategies to improve communication between nurses and patients/caregivers in an effort to promote shared decision-making, reduce adverse events, and improve adherence.
Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from AstraZeneca.
This activity is designed to meet the educational needs of oncology nurses who are involved in biomarker testing in NSCLC and related patient and caregiver conversations and decision-making.
- Review the biomarker pathology of advanced non-small cell lung cancer (NSCLC) and identify actionable oncogenic driver mutations.
- Appraise current guideline recommendations for comprehensive biomarker testing in NSCLC, and discuss the emerging utility of novel testing modalities, such as next generation sequencing (NGS) and ctDNA liquid biopsy.
- Evaluate currently available targeted treatment options for NSCLC, focusing on key differences in the safety and efficacy profiles of EGFR, ALK, ROS1, BRAF, and NTRK tyrosine kinase inhibitors (TKIs), and the appropriate selection and sequencing of these agents.
- Identify current barriers to targeted therapy in NSCLC management and consider strategies nurses can employ to optimize treatment, anticipate and manage toxicities, and promote patient adherence to oral therapies.
- Examine innovative ways oncology nurses can educate NSCLC patients and caregivers on biomarker testing and biomarker-driven treatment approaches, so as to enable patients to actively participate in shared decision-making.
Welcome Remarks and Introductions
The Importance of the Lung Cancer Team & Tumor Board
Personalizing Patient Care in NSCLC: Linking Testing to Treatments
Biomarker-Guided Treatment Approaches: New and Emerging Targeted Therapies for NSCLC
Talking to Patients & Caregivers about Comprehensive Biomarker Testing; Role Play on Shared Decision-Making (SDM) with LUNGevity Tip Sheet
Conversations with the Expert/Audience Q&A
Excerpts from CEC Oncology educational program, "Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine." Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP (Abramson Cancer Center) and Jill Feldman, MA (Patient and Founding Member of EGFR Resisters) discuss:
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP
Adult Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
University of Pennsylvania Medical Center
Advanced Senior Lecturer
University of Pennsylvania School of Nursing
Dr. Sherry is an Adult Oncology Nurse Practitioner for Thoracic Malignancies at the Abramson Cancer Center at the University of Pennsylvania Medical Center in Philadelphia, Pennsylvania. She is also an Advanced Senior Lecturer at the University of Pennsylvania School of Nursing where she teaches both undergraduate and graduate students. Dr. Sherry attended the Catholic University of America where she obtained her Bachelor of Science in Nursing and went on to receive her Masters in Nursing at the University of Pennsylvania where she graduated with a degree as an Adult Oncology Nurse Practitioner. Dr. Sherry went on to obtain her Doctor of Nursing Practice from Duke University where her dissertation focused on distress screening and management in patients with metastatic lung cancer. She is a member of the Oncology Nursing Society (ONS) and the Philadelphia Area Chapter of the Oncology Nursing Society (PACONS). She is also a member of the Xi Chapter of Sigma Theta Tau.
Jill Feldman, MA
Founding Member, EGFR Resisters
EGFR+ NSCLC since 2009
Mrs. Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her father and two grandparents to lung cancer within a period of eight months. Fourteen years later, her mom and close aunt succumbed to the disease within a two-year period. Jill was a volunteer, an advocate and past president of the LUNGevity Foundation before the unthinkable happened. In 2009, at 39 years old with four small children, Jill herself was diagnosed with lung cancer.
Jill has non-small cell lung cancer EGFR+ del exon 19. She has had two surgeries, stereotactic radiation therapy and is currently on targeted therapy. Lung cancer will be a lifelong roller coaster ride for Jill, but her family history illustrates the importance of research and the impact of advancements in prolonging and bettering lives for those living with lung cancer.
Jill continues to be involved with LUNGevity and remains on their patient advisory board. She is also the Deputy Chair of IASLC’s patient advisory board, a member of ECOG-ACRIN patient advocate board/thoracic committee and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research, formerly as a consumer reviewer, and currently as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Thoracic Oncology Symposium and by organizing independent lab tours in the Chicago area for patients and advocates. She has presented patient perspectives internationally at the World Conference on Lung Cancer hosted by IASLC and she recently co-authored the ASTRO Guidelines for SBRT in early stage lung cancer that was published in an ASCO special article in the Journal of Clinical Oncology.
Jill is honored to be a co-founder of the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFR+ lung cancer. She also continues to share her story in the media and at various events and participates in countless advocacy opportunities to shine a light on lung cancer and end the stigma associated with it.
Jill holds a Bachelor of Science in Business Communications from the University of Kansas, and a Master of Elementary Education from DePaul University. She works part time from home and spends her summers working at Culver Summer Schools and Camps in Culver, Indiana, where her children attend camp. She lives in Deerfield, Illinois with her husband, four children and two dogs.
Planner and Faculty Disclosures
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Joan B. Fowler, PharmD, BCPP–has no relevant financial relationships to disclose in relation to the content of this activity.
Jill Feldman, MA–has no relevant financial relationships to disclose in relation to the content of this activity.
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP–has no relevant financial relationships to disclose in relation to the content of this activity.
Mary Ellen Hand, RN, BSN-has disclosed that she is a consultant for AstraZeneca and Novartis.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is designated for 2.0 contact hours.
Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.
ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, AOCNS®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Coordination of Care, Professional Practice, and Psychosocial categories, and 2.0 points in Diagnosis and Staging, Disease-Related Biology, Oncology Nursing Practice, Scientific Basis for Practice, Symptom Management, and Treatment categories.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
- 2.00 ANCCIn support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is designated for 2.00 contact hour.
- 2.00 Participation